Endo International

Lazard Reports First-Quarter 2024 Results

Retrieved on: 
Giovedì, Aprile 25, 2024
Professional Services, Finance, Debt-to-GDP ratio, Sale, Avison Young, Service provider, Schaeffler Group, Enviva, Vitesco Technologies, Weather, CSR Limited, Lazard, AbbVie, Thomson Reuters, Francisco Partners, SVB, The Weather Company, Conference, Euronext Paris, Rubicon, Mars, Endo International, Tax, Silicon, Lumen Technologies, AUM, Acquisition, Mars, Incorporated, Massimo Zanetti Beverage Group, AFE, Share repurchase, Bank statement, Name, Asset management, GAAP, Sixth Street Partners, Note, Telescopic sight

On April 24, 2024, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.

Key Points: 
  • On April 24, 2024, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.
  • Beginning in the first quarter of 2024, Lazard has updated the names of certain non-U.S. GAAP ("non-GAAP") measures and metrics.
  • We believe that presenting our results on an adjusted basis, in addition to the U.S. GAAP results, is a meaningful and useful way to compare our operating results across periods.
  • ET on April 25, 2024, to discuss the company’s financial results for the first quarter of 2024.

Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer

Retrieved on: 
Mercoledì, Aprile 17, 2024
Sequence, Doctor of Philosophy, Wilfrid Sellars, University, Genomics, Molecular genetics, GSK plc, Partnership, Shire (pharmaceutical company), CNS, Endo International, Villanova University, Marketing, MBA, Oxford Biomedica, Louisiana State University, Drug discovery, Pharmaceutical industry

BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.

Key Points: 
  • Dr. Rasty brings 25+ years of experience in R&D, strategy, commercial, BD&L, and corporate leadership as the company advances novel, best-in-class medicines to treat CNS disorders
    BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.
  • "Sam's expertise will fuel our business development and commercial strategies as we continue to progress our lead programs towards the clinic," said Alexandra Glucksmann, Ph.D., Chief Executive Officer of Sensorium.
  • Dr. Rasty was most recently Chief Executive Officer of Sequence Bio, a genomics and precision medicine company in Canada, President and Chief Executive Officer of PlateletBio, a pioneering cell therapy biotechnology company in the Boston area, and Board Director of Oxford Biomedica, a UK-based gene therapy company.
  • Previously, he served as Chief Operating Officer at Homology Medicines, a genetic medicines company that he helped launch in early 2016 and transform into a fully integrated public gene therapy and gene editing company.

Decrease the Burden of Oncology Clinical Trials with Patient-Friendly Technologies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Mercoledì, Aprile 3, 2024
RN, Endo International, American Opportunity Tax Credit, Senior, Patient, Clinical trial, BSN, Cancer

TORONTO, April 3, 2024 /PRNewswire-PRWeb/ -- The burdens on oncology clinical trial participants are many. Professionals involved with the execution of clinical research should keep this top of mind when planning how to conduct a study. Patients, often feeling unwell even before the clinical trial commences, are impacted by every aspect of the experience, including the technologies they are required to use. One thing study teams can do to help minimize the burden on cancer patients is to seek technologies based on patient-centered design.

Key Points: 
  • In this free webinar, a former oncology clinical trial participant and cancer survivor—who is also a pharmaceutical R&D leader—will share some of her experiences as a clinical trial participant, including the impact of technology.
  • TORONTO, April 3, 2024 /PRNewswire-PRWeb/ -- The burdens on oncology clinical trial participants are many.
  • Professionals involved with the execution of clinical research should keep this top of mind when planning how to conduct a study.
  • In this webinar, a former oncology clinical trial participant and cancer survivor—who is also a pharmaceutical R&D leader—will share some of her experiences as a clinical trial participant, including the impact of technology.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Martedì, Marzo 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Martedì, Marzo 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Announces Confirmation of Plan of Reorganization

Retrieved on: 
Martedì, Marzo 19, 2024
Patient, United States bankruptcy court, Bankruptcy, Endo International, Plan, Sale, Growth, OTC, Pharmaceutical industry

DUBLIN, March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial restructuring.  Under the Plan, substantially all of the Company's assets are being sold to a new entity, Endo, Inc., over 95% of which is owned by holders of the Company's first lien debt.  The transaction is expected to close as early as late April 2024 upon receiving final regulatory approvals and satisfying customary closing conditions.

Key Points: 
  • DUBLIN, March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial restructuring.
  • Under the Plan, substantially all of the Company's assets are being sold to a new entity, Endo, Inc., over 95% of which is owned by holders of the Company's first lien debt.
  • The transaction is expected to close as early as late April 2024 upon receiving final regulatory approvals and satisfying customary closing conditions.
  • Blaise Coleman, Endo's President and Chief Executive Officer, said, "We look forward to emerging as Endo, Inc., a stronger company poised for sustained growth.

Endo Announces Confirmation of Plan of Reorganization

Retrieved on: 
Martedì, Marzo 19, 2024
Patient, United States bankruptcy court, Bankruptcy, Endo International, Plan, Sale, Growth, OTC, Pharmaceutical industry

DUBLIN, March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial restructuring.  Under the Plan, substantially all of the Company's assets are being sold to a new entity, Endo, Inc., over 95% of which is owned by holders of the Company's first lien debt.  The transaction is expected to close as early as late April 2024 upon receiving final regulatory approvals and satisfying customary closing conditions.

Key Points: 
  • DUBLIN, March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial restructuring.
  • Under the Plan, substantially all of the Company's assets are being sold to a new entity, Endo, Inc., over 95% of which is owned by holders of the Company's first lien debt.
  • The transaction is expected to close as early as late April 2024 upon receiving final regulatory approvals and satisfying customary closing conditions.
  • Blaise Coleman, Endo's President and Chief Executive Officer, said, "We look forward to emerging as Endo, Inc., a stronger company poised for sustained growth.

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution

Retrieved on: 
Martedì, Marzo 12, 2024
Online, Endo International, Brain, Exercise, Blood, Patient, Knowledge, Travel, Stroke, Hospital, Par, Prostacyclin, Death, Particulates, NDC, Orthostatic hypertension, Completeness, Heart, Water, Administration, FDA, Swelling, Food

The product is being recalled due to the potential for the presence of silicone particulates in the product solution.

Key Points: 
  • The product is being recalled due to the potential for the presence of silicone particulates in the product solution.
  • Administration of an injectable product that contains particulate matter may result in local irritation or swelling in response to the foreign material.
  • Treprostinil Injection 20mg/20mL (1mg/mL) is distributed in 20mL multidose vials as sterile solutions in water for injection, individually packaged in cartons under NDC #42023-206-01.
  • If you have further distributed the recalled product, please notify your accounts or any additional locations which may have received the recalled product.

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

Retrieved on: 
Giovedì, Febbraio 29, 2024
Ethics, OTC, Marketing, Corporate action, Culture, Internal Revenue Service, Endo International, DOJ, United States bankruptcy court, Average revenue per user, Cosmetic, Pharmaceutical industry

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER. The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER.
  • The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.
  • EHSI also agreed to resolve the DOJ's civil investigation of the sales and marketing of Opana® ER.
  • Endo submitted the DOJ resolutions to the Bankruptcy Court for approval, which Endo is seeking in conjunction with its proposed Plan of Reorganization.

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

Retrieved on: 
Giovedì, Febbraio 29, 2024
Ethics, OTC, Marketing, Corporate action, Culture, Internal Revenue Service, Endo International, DOJ, United States bankruptcy court, Average revenue per user, Cosmetic, Pharmaceutical industry

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER. The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER.
  • The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.
  • EHSI also agreed to resolve the DOJ's civil investigation of the sales and marketing of Opana® ER.
  • Endo submitted the DOJ resolutions to the Bankruptcy Court for approval, which Endo is seeking in conjunction with its proposed Plan of Reorganization.